Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasagiline in early Parkinson's disease
NCT00203060Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 1997
- Primary completion
- Jul 2000
- Modality
- Irreversible Covalent Inhibitors
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Rasagiline with Placebo (2 arms). Primary endpoint: Unified Parkinson's Disease Rating Scale Total Score at 26 weeks. Started Jul 1997; status: completed.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00203060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00203060.